Comparative Pharmacology
Head-to-head clinical analysis: PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN versus Q GESIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN versus Q GESIC.
PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN vs Q-GESIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Propoxyphene is a mu-opioid receptor agonist; acetaminophen inhibits cyclooxygenase (COX) and modulates central pain pathways.
Q-GESIC is a centrally acting non-opioid analgesic; its exact mechanism is unknown but may involve inhibition of cyclooxygenase (COX) and modulation of descending serotonergic and noradrenergic pathways.
One tablet (propoxyphene HCl 65 mg/acetaminophen 650 mg) orally every 4 hours as needed for pain; maximum: 6 tablets per day.
1-2 tablets (325-650 mg acetaminophen and 5-10 mg hydrocodone) orally every 4-6 hours as needed for pain; maximum 8 tablets per day.
None Documented
None Documented
Propoxyphene: 6-12 h (prolonged in hepatic disease); Norpropoxyphene (active metabolite): 30-36 h (accumulation risk). Acetaminophen: 2-3 h (prolonged in hepatic disease).
Terminal elimination half-life is 2-4 hours; clinical context: requires dosing every 4-6 hours for sustained analgesia.
Renal: Propoxyphene ~20-25% as unchanged drug and metabolites; Acetaminophen ~85-90% as glucuronide and sulfate conjugates, <5% unchanged. Fecal: Minimal for both.
Renal excretion of unchanged drug accounts for 60-70% of elimination; biliary/fecal excretion accounts for 20-30%; <5% metabolized via CYP enzymes.
Category C
Category C
Opioid Analgesic Combination
Opioid Analgesic Combination